Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 18 or older.
- People who have been referred for a routine screening mammogram that was done within 6 months before or will be done within 6 months after the blood draw, with no personal history of breast cancer (previous breast biopsies or prior abnormal mammogram results are allowed).
- People who have had a mammogram or MRI with abnormal results (classified as BIRADS 3, 4, or 5) that require further testing, with no personal history of breast cancer, where the blood draw takes place after the abnormal result but before any surgery or chemotherapy begins (confirm with trial site for exact timing details).
- People newly diagnosed with breast cancer — either invasive breast cancer or a type called DCIS — confirmed by biopsy within the past 60 days, who have not yet started any cancer treatment of any kind, at any stage.
- People with a history of early-stage breast cancer (stage 1, 2, or 3) who have completed their main treatments such as surgery, chemotherapy, or radiation and are currently in remission, with the blood draw happening at least 90 days after finishing those treatments. People still taking hormonal therapy are eligible, provided any CDK4/6 inhibitor therapy (a specific type of additional medication) has been completed beforehand.
Who may not be able to join:
- People who are not able to give informed consent.
- People who have received a blood transfusion within 14 days before the study blood draw.
- People who have had a heart attack, stroke, or pulmonary embolism (a blood clot in the lungs) within 3 months before the study blood draw.
- People who have had a surgical breast biopsy (where tissue is removed through a cut) within the past 30 days. A needle biopsy of the breast is permitted.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Anastasia Martynova, MD, University of Southern California
Phone: 323-865-0451
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Assess the sensitivity and specificity of LBx as a screening method for breast cancer
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.